Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard? [12]

Research output: Contribution to journalLetterpeer-review

2 Scopus citations

Fingerprint Dive into the research topics of 'Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard? [12]'. Together they form a unique fingerprint.